{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:27:33Z","timestamp":1789637253204,"version":"4.0.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Cervical cancer is common worldwide. Despite the existence of primary and secondary prevention strategies, the survival rate is decreasing in France due to an increasing proportion of advanced-stage cancer. Our objective was to determine the factors associated with a diagnosis of cervical cancer at advanced stages in an urban population in France.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective study was conducted on all consecutive records of patients diagnosed with cervical cancer between January 2006 and December 2018 in a single center in Paris. The data collected were demographic characteristics, medical and gynecological history, circumstances of diagnosis, diagnostic and therapeutic management. The patients were divided into two groups according to the FIGO 2018 stage at diagnosis: group A stages IA1 to IB2 and group B advanced stages IB3 to IVB.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 96 patients who were diagnosed with cervical cancer, 25 (26%) were in group A and 71 (74%) in group B. Women in group B had less frequently received regular gynecological care than in group A (36% vs 84.2%,\n p<\/jats:italic>\n \u2009<\u20090.001) and fewer had Pap test screening in the previous 3\u00a0years (30.4% vs 95.0%,\n p<\/jats:italic>\n \u2009<\u20090.001). Parity greater than 3 was more frequent in group B (69.6% vs 42.9%,\n p<\/jats:italic>\n \u2009=\u20090.031). The diagnosis was made during a routine examination or cervical smear in only 9.23% and 16.18% respectively in group B, versus 60% of cases in 45.82% of cases in group A (\n p<\/jats:italic>\n \u2009<\u20090.001 and\n p<\/jats:italic>\n \u2009=\u20090.003). Vaginal bleeding was observed in 85.29% in group B versus 36% in group A (\n p<\/jats:italic>\n \u2009<\u20090.001). Histological type was squamous cell carcinoma 87.32% of group B and 56% of group A (\n p<\/jats:italic>\n \u2009<\u20090.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Diagnosis of cervical cancers at advanced stages occurred mostly in women who did not benefit from the recommended screening. Universal access to screening is necessary for the prevention and early treatment of cervical cancer.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s12905-022-01668-3","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:04:47Z","timestamp":1648652687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diagnosis of advanced cervical cancer, missed opportunities?"],"prefix":"10.1186","volume":"22","author":[{"given":"J\u00e9r\u00e9mie","family":"Mattern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ir\u00e8ne","family":"Letendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Sibiude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"P\u00e9nager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Jnifen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata","family":"Souare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ayel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mandelbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"6","key":"1668_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"F Bray J Ferlay I Soerjomataram RL Siegel LA Torre A Jemal 2018 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 6 394 424 https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1668_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.respe.2013.11.073","volume":"62","author":"F Binder-Foucard","year":"2014","unstructured":"F Binder-Foucard N Bossard P Delafosse A Belot AS Woronoff L Remontet 2014 Cancer incidence and mortality in France over the 1980\u20132012 period: solid tumors Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique 62 2 95 108 https:\/\/doi.org\/10.1016\/j.respe.2013.11.073","journal-title":"Rev D\u00c9pid\u00e9miologie Sant\u00e9 Publique"},{"issue":"10167","key":"1668_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"PA Cohen A Jhingran A Oaknin L Denny 2019 Cervical cancer The Lancet 393 10167 169 182 https:\/\/doi.org\/10.1016\/S0140-6736(18)32470-X","journal-title":"The Lancet"},{"issue":"20","key":"1668_CR4","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1056\/NEJMp058171","volume":"353","author":"M Schiffman","year":"2005","unstructured":"M Schiffman PE Castle 2005 The promise of global cervical-cancer prevention N Engl J Med 353 20 2101 2104 https:\/\/doi.org\/10.1056\/NEJMp058171","journal-title":"N Engl J Med"},{"key":"1668_CR5","unstructured":"En R, Publique S. \u00c9tat Des Lieux et Recommandations Pour Le D\u00e9pistage Du Cancer Du Col de l\u2019ut\u00e9rus En France. 2010."},{"issue":"1","key":"1668_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.BULCAN.2016.11.003","volume":"104","author":"L Ribassin-Majed","year":"2017","unstructured":"L Ribassin-Majed G Teuff Le C Hill 2017 La fr\u00e9quence des cancers en 2016 et leur \u00e9volution Bull Cancer (Paris) 104 1 20 29 https:\/\/doi.org\/10.1016\/J.BULCAN.2016.11.003","journal-title":"Bull Cancer (Paris)"},{"issue":"1","key":"1668_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","volume":"152","author":"K Matsuo","year":"2019","unstructured":"K Matsuo H Machida RS Mandelbaum I Konishi M Mikami 2019 Validation of the 2018 FIGO cervical cancer staging system Gynecol Oncol 152 1 87 93 https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.026","journal-title":"Gynecol Oncol"},{"key":"1668_CR8","unstructured":"R\u00e9f\u00e9rentiel Cancers Du Col Ut\u00e9rin. 2016."},{"key":"1668_CR9","unstructured":"Cervical Cancer Pocket Guidelines."},{"key":"1668_CR10","doi-asserted-by":"crossref","unstructured":"Kosary CL. FIG0 Stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973\u201387 SEER Cases of Cancers of the Endometrium, Cervix, Ovary, Vulva, and Vagina KEY WORDS: Cox Proportional Hazards Model, Survival, Survival Rate, Cancer, All Sites 32 Kosary, vol. 10.","DOI":"10.1002\/ssu.2980100107"},{"issue":"6","key":"1668_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/fampra\/cmr033","volume":"28","author":"S Stapley","year":"2011","unstructured":"S Stapley W Hamilton 2011 Gynaecological symptoms reported by young women: examining the potential for earlier diagnosis of cervical cancer Fam Pract 28 6 592 598 https:\/\/doi.org\/10.1093\/fampra\/cmr033","journal-title":"Fam Pract"},{"issue":"6","key":"1668_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/cells8060622","volume":"8","author":"P Olusola","year":"2019","unstructured":"P Olusola HN Banerjee JV Philley S Dasgupta 2019 Human papilloma virus-associated cervical cancer and health disparities Cells 8 6 622 https:\/\/doi.org\/10.3390\/cells8060622","journal-title":"Cells"},{"key":"1668_CR13","unstructured":"SPF. Caract\u00e9risation des femmes ne r\u00e9alisant pas de d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus par frottis cervico-ut\u00e9rin en France. Num\u00e9ro th\u00e9matique. Vers la g\u00e9n\u00e9ralisation du d\u00e9pistage organis\u00e9 du cancer du col de l\u2019ut\u00e9rus. Accessed 29 Nov 2021. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/cancers\/cancer-du-col-de-l-uterus\/caracterisation-des-femmes-ne-realisant-pas-de-depistage-du-cancer-du-col-de-l-uterus-par-frottis-cervico-uterin-en-france.-numero-thematique.-vers"},{"issue":"9312","key":"1668_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(02)08151-5","volume":"359","author":"N Mu\u00f1oz","year":"2002","unstructured":"N Mu\u00f1oz S Franceschi C Bosetti 2002 Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study Lancet Lond Engl 359 9312 1093 1101 https:\/\/doi.org\/10.1016\/S0140-6736(02)08151-5","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"1668_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3917\/rdli.053.0003","volume":"53","author":"E Labbe","year":"2007","unstructured":"E Labbe JJ Moulin R Gueguen C Sass C Chatain L Gerbaud 2007 Un indicateur de mesure de la pr\u00e9carit\u00e9 et de la \u00absant\u00e9 sociale\u00bb: le score EPICES Rev Ires 53 1 3 https:\/\/doi.org\/10.3917\/rdli.053.0003","journal-title":"Rev Ires"},{"issue":"4","key":"1668_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3917\/spub.064.0513","volume":"18","author":"C Sass","year":"2006","unstructured":"C Sass R Gu\u00e9guen JJ Moulin 2006 Comparaison du score individuel de pr\u00e9carit\u00e9 des Centres d\u2019examens de sant\u00e9, EPICES, \u00e0 la d\u00e9finition socio-administrative de la pr\u00e9carit\u00e9 Sante Publique (Bucur) 18 4 513 522 https:\/\/doi.org\/10.3917\/spub.064.0513","journal-title":"Sante Publique (Bucur)"},{"key":"1668_CR17","first-page":"14","volume":"12","author":"M Berraho","year":"2012","unstructured":"M Berraho M Obtel K Bendahhou 2012 Sociodemographic factors and delay in the diagnosis of cervical cancer in Morocco Pan Afr Med J 12 14","journal-title":"Pan Afr Med J"},{"key":"1668_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/J.CANEP.2018.01.014","volume":"53","author":"TS Stewart","year":"2018","unstructured":"TS Stewart J Moodley FM Walter 2018 Population risk factors for late-stage presentation of cervical cancer in sub-Saharan Africa Cancer Epidemiol 53 81 92 https:\/\/doi.org\/10.1016\/J.CANEP.2018.01.014","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1668_CR19","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1186\/s12889-018-6065-6","volume":"18","author":"P Dunyo","year":"2018","unstructured":"P Dunyo K Effah EA Udofia 2018 Factors associated with late presentation of cervical cancer cases at a district hospital: a retrospective study BMC Public Health 18 1 1156 https:\/\/doi.org\/10.1186\/s12889-018-6065-6","journal-title":"BMC Public Health"},{"key":"1668_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001284","author":"MN Nassali","year":"2018","unstructured":"MN Nassali M Tadele RM Nkuba J Modimowame I Enyeribe E Katse 2018 Predictors of locally advanced disease at presentation and clinical outcomes among cervical cancer patients admitted at a tertiary hospital in Botswana Int J Gynecol Cancer https:\/\/doi.org\/10.1097\/IGC.0000000000001284","journal-title":"Int J Gynecol Cancer"},{"key":"1668_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-016-0285-7","author":"R Mlange","year":"2016","unstructured":"R Mlange D Matovelo P Rambau B Kidenya 2016 Patient and disease characteristics associated with late tumour stage at presentation of cervical cancer in northwestern Tanzania BMC Womens Health https:\/\/doi.org\/10.1186\/s12905-016-0285-7","journal-title":"BMC Womens Health"},{"key":"1668_CR22","unstructured":"InCa. G\u00e9n\u00e9ralisation du d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus\/\u00e9tude m\u00e9dico-\u00e9conomique\/Phase 1\u2014Ref\u202f: APDEPCCU16. Accessed 25 June 2019. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Generalisation-du-depistage-du-cancer-du-col-de-l-uterus-etude-medico-economique-Phase-1"},{"key":"1668_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/oxfordjournals.aje.a117485","volume":"141","author":"MT Fahey","year":"1995","unstructured":"MT Fahey L Irwig P Macaskill 1995 Meta-analysis of Pap test accuracy Am J Epidemiol 141 680 689","journal-title":"Am J Epidemiol"},{"key":"1668_CR24","unstructured":"PUBLIC HEALTH GUIDELINES SUMMARY Evaluation of Human Papillomavirus (HPV) tests for primary screening of precancerous and cancerous lesions of the cervix and the role of P16\/Ki67 dual immunostaining; 2019."},{"key":"1668_CR25","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ypmed.2019.04.010","volume":"123","author":"F Islami","year":"2019","unstructured":"F Islami SA Fedewa A Jemal 2019 Trends in cervical cancer incidence rates by age, race\/ethnicity, histological subtype, and stage at diagnosis in the United States Prev Med 123 316 323 https:\/\/doi.org\/10.1016\/j.ypmed.2019.04.010","journal-title":"Prev Med"},{"issue":"2","key":"1668_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1043\/1543-2165(2004)128<153:DOAISO>2.0.CO;2","volume":"128","author":"AA Renshaw","year":"2004","unstructured":"AA Renshaw DR Mody RL Lozano 2004 Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions Arch Pathol Lab Med 128 2 153 157 https:\/\/doi.org\/10.1043\/1543-2165(2004)128<153:DOAISO>2.0.CO;2","journal-title":"Arch Pathol Lab Med"},{"key":"1668_CR27","unstructured":"HAS. \u00c9valuation de la recherche des papillomavirus humains (HPV) en d\u00e9pistage primaire des l\u00e9sions pr\u00e9canc\u00e9reuses et canc\u00e9reuses du col de l\u2019ut\u00e9rus et de la place du double immuno-marquage p16\/Ki67."}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-022-01668-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-022-01668-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T15:05:06Z","timestamp":1648652706000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-022-01668-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1186\/s12905-022-01668-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-264517\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"21 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki). The study was approved by the French database security commission (Commission Nationale Informatique et Libert\u00e9) and by the Institutional Review Board (Comit\u00e9 d\u2019Evaluation de l\u2019\u00e9thique des projets de Recherche Biom\u00e9dicale, IRB00006477: N\u00b02019-038 January 31, 2020). Informed consent to participate was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No personally identifiable data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}